Article Details
Retrieved on: 2025-02-10 17:23:39
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Accord BioPharma's agreement with Bio-Thera Solutions to commercialize a biosimilar of Simponi (golimumab), highlighting the biopharmaceutical industry's initiatives to expand access to TNF inhibitors like golimumab for treating conditions such as psoriatic arthritis.
Article found on: pipelinereview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here